Category Archives: Regulators

FDA Warns of Bogus Pharmacy Sites

Buying Prescription Scam Alert 1Drugs Online May Be Dangerous Says Drug Enforcement Administration

DEA Logo - Buying Percription Drugs

National Association of Boards of Pharmacy (NABP)

Warning

“The Canadian Pharmacy, Canadian/European Pharmacy”, “Canadian Healthcare” and “US Drugstore” are brands of one of the most disgusting illegal online pharmacy group well organized CRIMINAL OPERATION of all times. “GREED” is the driving force behind this operation. Don’t let them fool you. They will never send you any genuine drugs. If they ever send anything at all, it may consist of literally anything from sugar to wall plaster, and they certainly don’t care that you will endanger your health by taking those dangerous counterfeit drugs.

Behind The Online Pharmacy

Today a shadowy, transnational network of illicit drug manufacturers, traders, doctors, Web site operators, spammers and criminals makes up the online pharmacy world.

Buying Medication Online Can Be Safe

There are many options out there when it comes to buying medication online. We have looked at websites after websites. Some sites feature offshore pharmacies that do not require a prior prescription. Others feature licensed pharmacies that do require a prescription from your doctor.
Before making a purchase that can effect your health, we strongly recommend that you consult your physician & DO NOT self-medicate. Ordering medication online can be a safe, money-saving experience. When done through licensed online pharmacies that require a prescription, you can be assured that the medication you get is exactly what you need to treat your ailments.


From: FDA Center for Drug Evaluation and Research
FDAlnternetPharmacyTaskForce-CDER@fda.hhs.gov

 

Date: November 16, 2009                                  

TO: Med Light LTD
37 Rectory Lane
PO Box 2063
Belize City, Belize

UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICES

FOOD AND DRUG ADMINISTRATION
ROCKVILLE, MD 20903

TO: Med Light LTD

FROM: Food and Drug Administration Internet Pharmacy Task Force

RE: Internet Marketing of Unapproved and Misbranded Drugs

DATE: November 16, 2009

Warning Letter

The United States Food and Drug Administration (FDA) has reviewed your websites at

and has determined that you are offering products for sale in violation of the Federal Food, Drug, and Cosmetic Act (the Act). These products include, but are not limited to, “Acomplia (Brand),” “Acomplia (Generic),” “Rimonabant,” “Viagra (Brand),” “Cialis (Brand),” and “Prozac (Generic).” We request that you immediately cease marketing violative products.

These products are drugs under section 201 (g) of the Act, 21 U.S.C. § 321(g), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or because they are intended to affect the structure or function of the body. Your marketing and distribution of these drugs violate various provisions of the Act, as described below:

Unapproved New Drugs

Your firm offers many unapproved new drugs including, but not limited to “Acomplia (Brand),” “Acomplia (Generic),” and “Rimonabant.” FDA is taking this action against your firm because of the inherent risk in buying unapproved prescription drugs. Unapproved drugs from unregulated sources do not have the same assurance of safety and effectiveness as drugs subject to FDA oversight and have been found to be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether. For drugs that are regulated by FDA, FDA protections include rigorous scientific standards for prescription drug approval and label review for accuracy and completeness, manufacturing procedures and testing performed under closely controlled conditions at FDA-registered and inspected facilities. In addition, pharmacies and wholesalers who sell or distribute prescription drugs in the U.S. are licensed by the states.

Unapproved new drugs delivered to the American public from unregulated sources may not be safe and effective. Rimonabant (also marketed under the name Acomplia) was specifically rejected for FDA approval because it did not meet the statutory requirements for safety and effectiveness. In June 2007, the FDA Endocrinologic and Metabolic Drugs Advisory Committee unanimously voted not to recommend approval of the drug because of increased risk of neurological and psychiatric side effects including seizures, depression, anxiety, insomnia, aggressiveness, and suicidal thoughts among patients. Accordingly, the “Acomplia (Brand),” “Acomplia (Generic),” and “Rimonabant” dispensed through your websites are “new drugs,” as defined by section 201 (p) of the Act, 21 U.S.C. § 321(p).

Under sections 301 (d) and 505(a) of the Act, 21 U.S.C. §§ 331 (d) and 355(a), a new drug may not be introduced or delivered for introduction into interstate commerce unless an FDA-approved application is in effect for it. Your sale of several products, including “Acomplia (Brand),” “Acomplia (Generic),” and “Rimonabant” without approved applications violates these provisions of the Act.

Misbranded Drugs

Your websites offer product for sale without requiring that the products be dispensed under a prescription from a duly licensed practitioner, including, but not limited to “Viagra (Brand),” “Cialis (Brand),” and “Prozac (Generic).” Therefore, the drugs are misbranded under section 503(b)(1) of the Act, 21 U.S.C. § 353(b)(1), and are marketed in violation of sections 301(a), 301(b), and 301(k) of such Act, 21 U.S.C. §§ 331(a), 331(b), and 331(k).

Further, your websites offer products for sale and state that they are FDA-approved. As noted above, your products are not FDA-approved and are offered for sale in violation of the Act. Therefore, these products are misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because the labeling of the drugs is false and misleading.

The introduction or delivery for introduction into interstate commerce of these misbranded products violates section 301(a) of the Act, 21 U.S.C. § 331(a).

This letter is not intended to identify all of the ways in which your activities might be in violation of United States law. It is your responsibility to ensure that all products marketed by your firm are in compliance with the Act and its implementing regulations. You should take prompt action to correct the violations noted above. Failure to correct these violations promptly may result in regulatory action, including but not limited to, seizure and/or injunction without further notice.

Please notify this office in writing within 15 working days of receipt of this letter of any steps you have taken or will take to correct the noted violations and to prevent their recurrence. If the corrective action(s) cannot be completed within 15 working days, state the reason for the delay and the time within which the correction(s) will be completed. Your response should be sent to FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov. Please direct any inquiries concerning this letter to FDA’s Internet Pharmacy Task Force at FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov or (301) 796-3110.

Sincerely,

/S/
Deborah M. Autor, Esq.
Director
Office of Compliance
Center for Drug Evaluation and Research

CC:
Chris Walsh c/o Dynadot Privacy
PO Box 701
San Mateo, CA 94401
http://www.refill-rx-meds.com
http://www.brand-meds.com
http://www.rx-easy-pharmacy.com

Janis Larsen c/o Dynadot Privacy
PO Box 701
San Mateo, CA 94401
http://www.buy-american-pharma.com
http://www.online-pharma-rx.com

Gordon Mcleod c/o Dynadot Privacy
PO Box 701
San Mateo, CA 94401
http://www.first-american-pharmacy.com
http://www.secure-rx-refills.com

Katherine Wainscott c/o Dynadot Privacy
PO Box 701
San Mateo, CA 94401
http://www.brand-pharma.com

PrivacyProtect.org
Domain Administrator
contact@privacyprotect.org
http://www.american-pharm.com
http://www.first-swiss-meds.com

Jacqueline Sockley c/o Dyndadot Privacy
PO Box 701
San Mateo, CA 94401
http://www.rx-Iife.com

Domains by Proxy, Inc.
15111 N. Hayden Road
Ste 160 PMB 353
Scottsdale Arizona 85260
http://www.quickgeneric.com


Other Domains Associated With This Group

  • healthonlineshop.org
  • rollinrollin.net
  • newhealthshop.net
  • generics-pharm.net
  • megarx.net
  • cheapphentermine.com
  • mediwax.com
  • buy-refill-online.com
  • easy-refill-online.com
  • my-refill-club.com
  • improved-generic.com
  • global-genrics-source.com
  • global-rx-pharm.com
  • us-value-pharm.com
  • i-want-rx.com
  • global-meds-direct.com
  • pharma-herbal.com
  • first-refill-club.com
  • first-refill-online.com
  • approved-refill-club.com
  • refill-club.com
  • refill-online.com
  • hotrxsales.com
  • lifestyle-generic.com
  • refill-rx-now.com
  • direct-rx-refill.com
  • central-rx-refill.com
  • my-refill-drugstore.com
  • secure-rx-refills.com
  • global-drugstore.com
  • refill-drugstore.com
  • pharma-discounts.com
  • global-pharma-rx.com
  • wehatebaseball.com
  • checkfornews.com
  • total-pharma.com
  • us-pharmacy.us
  • trusted-tabs.us
  • terameds.org
  • rxmeds-online.net
  • buyonlineviagra.net
  • usrxmeds.net
  • mypillshop.net
  • buycanadianpharmacy.net
  • dutyfreemeds.net
  • happypharmacy.net
  • cheapestcigarettes.net
  • buy-order.net
  • drug-pharmacy.net
  • rx-market.info
  • preferredpharma.com
  • prescriptionsintl.com
  • quickgeneric.com
  • 1st-european-pharmacy.com
  • e-pharmacy-usa.com
  • webrxmed.com
  • online-pharmacy-no-prescription.com
  • pillsshipping.com
  • buycanadianpharmacy.com
  • cheapdrugsmd.com
  • domain-admin-central.com
  • aprixe.com
  • pricedpills.com
  • medscourier.com
  • de-pharma.com
  • my-pill.com
  • rxgenericsstore.com
  • herbalmedsonline.com
  • global-generics-source.com
  • rxcalm.com
  • allgenericpills.com
  • nonrxmeds.com
  • pharmacytouch.com
  • mypillsfinder.com
  • bestrxdeal.com
  • phentermine-online-shop.com
  • bitrhconrtol.com
  • 2009drugs.com
  • americanmedsdirect.com
  • first-canadian-drugstore.com
  • first-canadian-pharmacy.com
  • first-canadian-meds.com
  • first-canadian-pharma.com
  • rxbynet.com
  • top-hotpills.com
  • 4cheaprx.com
  • top-uspharm.com
  • discountwebmeds.com
  • doctorphentermine.com
  • scandiamedic.com
  • reliable-medicines.com
  • drugstrain.com
  • online-generic-pharmacy.com
  • buy-generic-drugs-online.com
  • medrugsleader.com
  • pillspricedright.com
  • dprixe.com
  • drugdeliverycenter.com
  • pharmacy-usa.biz
  • ukmed.biz
  • duty-free-cigarettes.biz

 

FDA Warns of Bogus Pharmacy Sites

Buying Prescription Scam Alert 1
Drugs Online May Be Dangerous Says Drug Enforcement Administration


DEA Logo - Buying Percription Drugs

National Association of Boards of Pharmacy (NABP)

Warning

“The Canadian Pharmacy, Canadian/European Pharmacy”, “Canadian Healthcare” and “US Drugstore” are brands of one of the most disgusting illegal online pharmacy group well organized CRIMINAL OPERATION of all times. “GREED” is the driving force behind this operation. Don’t let them fool you. They will never send you any genuine drugs. If they ever send anything at all, it may consist of literally anything from sugar to wall plaster, and they certainly don’t care that you will endanger your health by taking those dangerous counterfeit drugs.

Behind The Online Pharmacy

Today a shadowy, transnational network of illicit drug manufacturers, traders, doctors, Web site operators, spammers and criminals makes up the online pharmacy world.

Buying Medication Online Can Be Safe

There are many options out there when it comes to buying medication online. We have looked at websites after websites. Some sites feature offshore pharmacies that do not require a prior prescription. Others feature licensed pharmacies that do require a prescription from your doctor.
Before making a purchase that can effect your health, we strongly recommend that you consult your physician & DO NOT self-medicate. Ordering medication online can be a safe, money-saving experience. When done through licensed online pharmacies that require a prescription, you can be assured that the medication you get is exactly what you need to treat your ailments.

 


From: FDA Center for Drug Evaluation and Research
FDAlnternetPharmacyTaskForce-CDER@fda.hhs.gov

Date: November 16, 2009

 

TO: New Horizons LTD                                                                        
Prol. Av. Independencia KM 20
Santo Domingo
Dominican Republic

UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
ROCKVILLE, MD.20903

TO: New Horizons LTD
FROM: Food and Drug Administration Internet Pharmacy Task Force
RE:  Internet Marketing of Unapproved and Misbranded Drugs
DATE: November 16, 2009

Warning Letter

The United States Food and Drug Administration (FDA) has reviewed your websites at

and has determined that you are offering products for sale in violation of the Federal Food, Drug, and Cosmetic Act (the Act). These products include, but are not limited to, “Acomplia (Generic),” “Acomplia (Brand),” “Rimonabant,” “Viagra (Brand),” “Cialis (Brand),” “Prozac (Generic),” and “Levitra (Brand).” We request that you immediately cease marketing violative products.

These products are drugs under section 201 (g) of the Act, 21 U.S.C. § 321 (g), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or because they are intended to affect the structure or function of the body. Your marketing and distribution of these drugs violate various provisions of the Act, as described below:

Unapproved New Drugs

Your firm offers many unapproved new drugs including, but not limited to “Acomplia (Generic),” “Acomplia (Brand),” and “Rimonabant.” FDA is taking this action against your firm because of the inherent risk in buying unapproved prescription drugs. Unapproved drugs from unregulated
sources do not have the same assurance of safety and effectiveness as drugs subject to FDA oversight and have been found to be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether. For drugs that are regulated by FDA, FDA protections include rigorous scientific standards for prescription drug approval and label review for accuracy and completeness, manufacturing procedures and testing performed under closely controlled conditions at FDA-registered and inspected facilities. In addition, pharmacies and wholesalers who sell or distribute prescription drugs in the U.S. are licensed by the states. Unapproved new drugs delivered to the American public from unregulated sources may not be safe and effective.

Rimonabant (also marketed under the name Acomplia) was specifically rejected for FDA approval because it did not meet the statutory requirements for safety and effectiveness. In June 2007, the FDA Endocrinologic and Metabolic Drugs Advisory Committee unanimously voted not to recommend approval of the drug because of increased risk of neurological and psychiatric side effects including seizures, depression, anxiety, insomnia, aggressiveness, and suicidal thoughts
among patients. Accordingly, the”Acomplia (Generic),·  Acomplia(Brand),· and “Rimonabant”
dispensed through your websites are “new drugs,” as defined by section 201(p) of the Act, 21 U.S.C. § 321(p).

Under sections 301 (d) and 505(a) of the Act, 21 U.S.C. §§ 331 (d) and 355(a), a new drug may not be introduced or delivered for introduction into interstate commerce unless an FDA-approved application is in effect for it. Your sale of several products, including “Acomplia (Generic), “Acomplia (Brand),” and “Rimonabant” without approved applications violates these provisions of the Act.

Misbranded Drugs

Many of your websites sell products, including but not limited to “Viagra (Brand),” “Cialis (Brand)”, “Prozac (Generic),” and “Levitra (Brand)” without requiring that the products be dispensed under a prescription from a duly licensed practitioner. Therefore, the drugs are misbranded under section 503(b)(1) of the Act, 21 U.S.C. § 353(b)(1), and are marketed in violation of sections 301(a), 301 (b), and 301(k) of such Act, 21 U.S.C. §§ 331 (a), 331(b), and 331(k).

Further, your websites offer products for sale and state that they are FDA-approved. As noted above, your products are not FDA-approved and are offered for sale in violation of the Act.
Therefore, these products are misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because the labeling of the drugs is false and misleading.

The introduction or delivery for introduction into interstate commerce of these misbranded products violates section 301 (a) of the Act, 21 U.S.C. § 331 (a).

This letter is not intended to identify all of the ways in which your activities might be in violation of United States law. It is your responsibility to ensure that all products marketed by your firm are in compliance with the Act and its implementing regulations. You should take prompt action to correct the violations noted above. Failure to correct these violations promptly may result in regulatory action, including but not limited to, seizure and/or injunction without further notice.

Please notify this office in writing within 15 working days of receipt of this letter of any steps you have taken or will take to correct the noted violations and to prevent their recurrence. If the corrective action(s) cannot be completed within 15 working days, state the reason for the delay and the time within which the correction(s) will be completed. Your response should be sent to FDAlnternetPharmacyTaskForce-CDER@fda.hhs.gov. Please direct any inquiries concerning this letter to FDA’s Internet Pharmacy Task Force at FDAlnternetPharmacyTaskForceCDER@ fda.hhs.govor (301) 796-3110.

Sincerely,

/S/
Deborah M. Autor, Esq.
Director
Office of Compliance
Center for Drug Evaluation and Research

Cc:
Chris Walsh c/o Dynadot Privacy
PO Box 701
San Mateo, CA 94401
United States
top-drugstore. net

John Ruben c/o Dynadot Privacy
PO Box 701
San Mateo, CA 94401
United States
us-rx-meds.com

PrivacyProtect.org
Domain Admin
contact@privacyprotect.org
american-pharma.com
approved-swiss-pharm.com
approved-swiss-pharma.com
approved-swiss-pharmacy.com
first-swiss-dru gstore.com
first-swiss-pharm .com
first-swiss-pharmacy.com
mexican-pharma.com

Gordon Mcleod c/o Dynadot Privacy
PO Box 701
San Mateo, CA 94401
United States
central-rx-refill.com

Piter Krasnikov
745 Ushakova
Petersburg, 23987
Russian Federation
midas ua@yahoo.com
cheapdrugsmd.com

Domains by Proxy, Inc., DomainsByProxy.com
15111 N. Hayden Rd., Ste 160, PMB 353
Scottsdale, Arizona 85260
PHARMACYTOUCH.COM@domainsbyproxy.com
pharmacytouch.com

WhoisGuard
8939 S. Sepulveda Blvd. #110 – 732
Westchester, CA 90045
lion-rx.com
mypillshop.com

 


 

Other Domains Assoiciated With This Group

  1. stimulmedia.us                                                     
  2. stimul-media.org
  3. stimulmedia.org
  4. x-traffic.org
  5. indianmeds.org
  6. stimulmedia.net
  7. indianrx.net
  8. pharmaceutical-news.net
  9. stimulmedia.info
  10. anti-fungal-meds.com
  11. anti-headache-meds.com
  12. bp-meds.com
  13. cheap-anti-depressants.com
  14. cheap-ed-drugs.com
  15. cheap-ed-meds.com
  16. cheap-ed-pills.com
  17. cheap-pain-meds.com
  18. discount-ed-meds.com
  19. discount-ed-pills.com
  20. extracheapdrugs.com
  21. gastrointestinal-meds.com
  22. get-your-movie.com
  23. gpills.com
  24. help-me-please.com
  25. mens-best-friends.com
  26. order-cheap-antibiotics.com
  27. order-cheap-cialis.com
  28. order-cheap-levitra.com
  29. pills4boys.com
  30. pr-drugs.com
  31. stimulmedia.com
  32. stimul-media.com
  33. thyroid-meds.com
  34. womens-health-meds.com
  35. deli-drugs.com
  36. delirx.com
  37. delidrugs.com
  38. delhi-drugs.com
  39. delhidrugs.com
  40. delhirx.com
  41. perfect-ed-store.com
  42. top-viagra-store.com
  43. worlds-best-pharmacy.com
  44. worldbestpharmacy.com
  45. ordercheappills.com
  46. bestdealviagra.com
  47. yourpillshere.com
  48. genericsfromindia.com
  49. indian-generics.com
  50. secure-my-card.com
  51. mumbaidrugs.com
  52. my-secure-billing.com
  53. best-cialis-store.com
  54. friendly-ed-pharmacy.com
  55. popular-ed-products.com
  56. best-levitra-store.com
  57. rxpforum.com
  58. rxpblog.com
  59. rxpwiki.com
  60. smok-ox.com
  61. smokox.com
  62. regrowth-plus.com
  63. yagarastock.com
  64. fast-slim.com
  65. naturalexcel.com
  66. hoodiastock.com
  67. fineandchic.com
  68. yourorderhere.com
  69. herbalcustomer.com
  70. billclothes.com
  71. paid4clothes.com
  72. bigp-rx.com
  73. megahoodia400.com
  74. well-sleep.com
  75. purplehoodia800.com
  76. hghgreen.com
  77. garments-replica.com
  78. salezhelp.com
  79. indian-herbals.com
  80. naturalpenisole.com
  81. servized.com
  82. medsbill.com
  83. paid4medz.com
  84. your-pills-online.com
  85. easy-export.biz
  86. farmaforum.biz
  87. pharmforum.biz

FDA Warning – 247meds. com

Buying Prescription Scam Alert 1Drugs Online May Be Dangerous Says Drug Enforcement Administration


DEA Logo - Buying Percription Drugs

National Association of Boards of Pharmacy (NABP)

Warning

“The Canadian Pharmacy, Canadian/European Pharmacy”, “Canadian Healthcare” and “US Drugstore” are brands of one of the most disgusting illegal online pharmacy group well organized CRIMINAL OPERATION of all times. “GREED” is the driving force behind this operation. Don’t let them fool you. They will never send you any genuine drugs. If they ever send anything at all, it may consist of literally anything from sugar to wall plaster, and they certainly don’t care that you will endanger your health by taking those dangerous counterfeit drugs.

Behind The Online Pharmacy

Today a shadowy, transnational network of illicit drug manufacturers, traders, doctors, Web site operators, spammers and criminals makes up the online pharmacy world.

Buying Medication Online Can Be Safe

There are many options out there when it comes to buying medication online. We have looked at websites after websites. Some sites feature offshore pharmacies that do not require a prior prescription. Others feature licensed pharmacies that do require a prescription from your doctor.
Before making a purchase that can effect your health, we strongly recommend that you consult your physician & DO NOT self-medicate. Ordering medication online can be a safe, money-saving experience. When done through licensed online pharmacies that require a prescription, you can be assured that the medication you get is exactly what you need to treat your ailments.


From: FDA Center for Drug Evaluation and Research
FDAlnternetPharmacyTaskForce-CDER@fda.hhs.gov

Date: November 16, 2009                                                          


TO: Ric Deleon
21 Villamor Street
Manila, Manila 2700
bastprices2000@yahoo.com
UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
ROCKVILLE, MD 20903

TO: Ric Deleon
FROM: Food and Drug Administration Internet Pharmacy Task Force
RE: Internet Marketing of Unapproved and Misbranded Drugs
DATE: November 16, 2009

WARNING LETTER

The United States Food and Drug Administration (FDA) has reviewed your websites at

and has determined that you are offering products for sale in violation of the Federal Food, Drug, and Cosmetic Act (the Act). These products include, but are not limited to, “Acomplia (Generic),” “Acomplia (Brand),” “Rimonabant,” “Herbal Xanax,” “Herbal Ambien,” “Herbal Viagra,” “Viagra (Brand),” “Xanax (Brand),” and “Valium (Brand).” We request that you immediately cease marketing violative products.

These products are drugs under section 201 (g) of the Act, 21 U.S.C. § 321 (g), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or because they are intended to affect the structure or function of the body. Your marketing and distribution of these drugs violate various provisions of the Act, as described below:

Unapproved New Drugs

Your firm offers many unapproved new drugs including, but not limited to Acomplia (Generic),” “Acomplia (Brand),” “Rimonabant,” “Herbal Xanax,· “Herbal Ambien,· and “Herbal Viagra.” FDA
is taking this action against your firm because of the inherent risk in buying unapproved prescription drugs. Unapproved drugs from unregulated sources do not have the same assurance of safety and effectiveness as drugs subject to FDA oversight and have been found to be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether. For drugs that are regulated by FDA, FDA protections include rigorous scientific standards for prescription drug approval and label review for accuracy and completeness, manufacturing procedures and testing performed under closely controlled conditions at FDA-registered and inspected facilities. In addition, pharmacies and wholesalers who sell or distribute prescription drugs in the U.S. are licensed by the states. Unapproved new drugs delivered to the American public from unregulated sources may not be safe and effective.

Rimonabant (also marketed under the name Acomplia) was specifically rejected for FDA approval because it did not meet the statutory requirements for safety and effectiveness. In June 2007, the FDA Endocrinologic and Metabolic Drugs Advisory Committee unanimously voted not to recommend approval of the drug because of increased risk of neurological and psychiatric side effects including seizures, depression, anxiety, insomnia, aggressiveness, and suicidal thoughts
among patients. Accordingly, the “Acomplia (Generic),” “Acomplia (Brand),” and “Rimonabant,” dispensed through your websites are “new drugs,” as defined by section 201 (p) of the Act, 21 U.S.C. § 321(p), because it is not generally recognized as safe and effective for its labeled uses.

You also offer “Herbal Xanax,” “Herbal Ambien,” and “Herbal Viagra” on your websites. Xanax, Ambien, and Viagra are approved drugs well-known for their intended use(s) to treat disease.
Therefore, including these drug names causes “Herbal Xanax,” “Herbal Ambien,” and “Herbal Viagra” to be subject to regulation as drugs under Section 201 (g) of the Act because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease.
Moreover, these products are new drugs, as defined by section 201 (p) of the Act, 21 U.S.C. § 321 (p).

Under sections 301 (d) and 505(a) of the Act, 21 U.S.C. §§ 331 (d) and 355(a), a new drug may not be introduced or delivered for introduction into interstate commerce unless an FDA-approved application is in effect for it. Your sale of several products, including but not limited to “Acomplia (Generic),” “Acomplia (Brand),” “Rimonabant,” “Herbal Xanax,” “Herbal Ambien,” and “Herbal Viagra,” without approved applications violates these provisions of the Act.

Misbranded Drugs

Your websites offer several products, including but not limited to “Viagra (Brand),” “Xanax (Brand),” and “Valium (Brand),” for sale without requiring that the products be dispensed under a prescription from a duly licensed practitioner. Some of the products available on your website are also controlled substances; the sale of these products is particularly concerning because of the potential for abuse and dependency. Therefore, the drugs are misbranded under section
503(b)(1) of the Act, 21 U.S.C. § 353(b)(1), and are marketed in violation of sections 301 (a), 301 (b), and 301 (k) of such Act, 21 U.S.C. §§ 331 (a), 331 (b), and 331 (k).

Further, your websites offer products for sale and state that they are FDA-approved. As noted above, your products are not FDA-approved and are offered for sale in violation of the Act.
Therefore, these products are misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because the labeling of the drugs is false and misleading.

In addition, you offer “Herbal Xanax,” “Herbal Ambien,” and “Herbal Viagra” for sale. These drugs are misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because the labeling of the drugs are false and misleading. The labeling are false and misleading because they erroneously suggest that the products contain Xanax, Ambien, and Viagra, which are the proprietary names for FDA-approved products containing the active pharmaceutical ingredients alprazolam,
zolpidem, and sildenafil citrate. Regardless of whether your products contain Xanax, Ambien, or Viagra, the products you are offering for sale are not manufactured by the sponsors of the approved applications for Xanax, Ambien, or Viagra, and it is false and misleading to suggest that
your products are manufactured by that sponsor.

The introduction or delivery for introduction into interstate commerce of these misbranded products violates section 301 (a) of the Act, 21 U.S.C. § 331 (a).

This letter is not intended to identify all of the ways in which your activities might be in violation of United States law. It is your responsibility to ensure that all products marketed by your firm are in compliance with the Act and its implementing regulations. You should take prompt action to correct the violations noted above. Failure to correct these violations promptly may result in regulatory action, including but not limited to, seizure and/or injunction without further notice.

Please notify this office in writing within 15 working days of receipt of this letter of any steps you have taken or will take to correct the noted violations and to prevent their recurrence. If the corrective action(s) cannot be completed within 15 working days, state the reason for the delay and the time within which the correction(s) will be completed. Your response should be sent to FDAlnternetPharmacyTaskForce-CDER@fda.hhs.gov. Please direct any inquiries concerning this letter to FDA’s Internet Pharmacy Task Force at FDAlnternetPharmacyTaskForceCDER@fda.hhs.gov or (301) 796-3110.
Sincerely,

/S/

Deborah M. Autor, Esq.
Director
Office of Compliance


Address lookup

lookup failed 247meds. com
Could not find an IP address for this domain name.

Domain Whois record

Queried with “247meds. com”…

Query error: NoWhoisServerForDomain

Network Whois record

Don’t have an IP address for which to get a record

DNS records

DNS query for 247meds. com returned an error from the server: NameError

No records to display
— end –


IP address: 66.115.142.93
Host name: 247meds.com
Alias:
247meds.com
66.115.142.93 is from United States(US) in region North America

TraceRoute to 66.115.142.93 [247meds.com]
Hop (ms) (ms) (ms) IP Address Host name
1 30 61 57 72.249.128.5 -
2 52 35 11 8.9.232.73 xe-5-3-0.edge3.dallas1.level3.net
3 7 18 30 4.69.145.244 ae-93-90.ebr3.dallas1.level3.net
4 55 26 36 4.69.134.22 ae-7-7.ebr3.atlanta2.level3.net
5 32 31 26 4.69.148.254 ae-73-73.csw2.atlanta2.level3.net
6 33 28 28 4.69.150.68 ae-22-52.car2.atlanta1.level3.net
7 29 26 25 4.78.211.162 nationalnet.atlanta1.level3.net
8 30 35 44 66.115.128.114 gig2-10.tr1.atl4.national-net.com
9 62 57 42 66.115.142.93 pillcart.com
Trace complete

Retrieving DNS records for 247meds.com…
DNS servers
ns2.nationalnet.com
ns1.nationalnet.com

Answer records
247meds.com NS ns1.nationalnet.com 900s
247meds.com A 66.115.142.93 900s
247meds.com SOA
server: ns1.nationalnet.com
email: dnsadmin@nationalnet.com
serial: 2008042501
refresh: 28800
retry: 7200
expire: 604800
minimum ttl: 86400
900s
247meds.com NS ns2.nationalnet.com 900s

Authority records

Additional records
ns1.nationalnet.com A 216.201.81.254 900s
ns2.nationalnet.com A 216.201.87.28 900s

Whois query for 247meds.com
Results returned from whois.internic.net:

Domain Name: 247MEDS.COM
Registrar: GODADDY.COM, INC.
Whois Server: whois.godaddy.com
Referral URL: http://registrar.godaddy.com
Name Server: NS1.NATIONAL-NET.COM
Name Server: NS2.NATIONAL-NET.COM
Status: clientDeleteProhibited
Status: clientRenewProhibited
Status: clientTransferProhibited
Status: clientUpdateProhibited
Updated Date: 20-dec-2010
Creation Date: 11-mar-2003
Expiration Date: 11-mar-2012

Last update of whois database: Thu, 13 Jan 2011 11:43:14 UTC
Registrant:
Ric Deleon

Registered through: GoDaddy.com, Inc. (http://www.godaddy.com)
Domain Name: 247MEDS.COM

Domain servers in listed order:
NS1.NATIONAL-NET.COM
NS2.NATIONAL-NET.COM

For complete domain details go to:

http://who.godaddy.com/whoischeck.aspx?Domain=247MEDS.COM

Network IP address lookup:

Whois query for 66.115.142.93
Results returned from whois.arin.net:

The following results may also be obtained via:

http://whois.arin.net/rest/nets;q=66.115.142.93?showDetails=true&showARIN=false

NationalNet, Managed Services NATNET-MANAGED-VL255-BLK14 (NET-66-115-142-0-1) 66.115.142.0 – 66.115.142.255
NationalNet, Inc. NATIONALNET-1 (NET-66-115-128-0-1) 66.115.128.0 – 66.115.191.255

ARIN WHOIS data and services are subject to the Terms of Use
available at: https://www.arin.net/whois_tou.html

Results returned from whois.arin.net:

The following results may also be obtained via:

http://whois.arin.net/rest/nets;handle=NET-66-115-142-0-1?showDetails=true&showARIN=false

NetRange: 66.115.142.0 – 66.115.142.255
CIDR: 66.115.142.0/24
OriginAS: AS22384
NetName: NATNET-MANAGED-VL255-BLK14
NetHandle: NET-66-115-142-0-1
Parent: NET-66-115-128-0-1
NetType: Reassigned
RegDate: 2010-04-21
Updated: 2010-04-21
Ref: http://whois.arin.net/rest/net/NET-66-115-142-0-1

CustName: NationalNet, Managed Services
Address: 1130 Powers Ferry Place SE
City: Marietta
StateProv: GA
PostalCode: 30067
Country: US
RegDate: 2010-04-21
Updated: 2010-04-21
Ref: http://whois.arin.net/rest/customer/C02472880

OrgNOCHandle: NNO76-ARIN
OrgNOCName: NationalNet Network Operations
OrgNOCPhone: +1-678-247-7000
OrgNOCEmail: noc@nationalnet.com
OrgNOCRef: http://whois.arin.net/rest/poc/NNO76-ARIN

OrgTechHandle: IA88-ARIN
OrgTechName: IP Administrator
OrgTechPhone: +1-678-247-7000
OrgTechEmail: ipadmin@nationalnet.com
OrgTechRef: http://whois.arin.net/rest/poc/IA88-ARIN

OrgAbuseHandle: NAC69-ARIN
OrgAbuseName: NationalNet Abuse Contact
OrgAbusePhone: +1-678-247-7000
OrgAbuseEmail: abuse@nationalnet.com
OrgAbuseRef: http://whois.arin.net/rest/poc/NAC69-ARIN

RTechHandle: IA88-ARIN
RTechName: IP Administrator
RTechPhone: +1-678-247-7000
RTechEmail: ipadmin@nationalnet.com
RTechRef: http://whois.arin.net/rest/poc/IA88-ARIN

ARIN WHOIS data and services are subject to the Terms of Use
available at: https://www.arin.net/whois_tou.html


Other Known Domains Associated With This Group

  1. stimulhosting.com
  2. medpill.stimulhosting.com
  3. 247-meds.com
  4. relay.247-meds.com
  5. abouthealthy.com
  6. afmstore.com
  7. alfapills.com
  8. all-medication.com
  9. artelimbo.com
  10. best-pills-online.com
  11. bestpharmacyonline.net
  12. buy-pharmacy.info
  13. calidrugs.net
  14. ciais.net
  15. cvs-pharmacy.biz
  16. drug-store-online.net
  17. drugs24.net
  18. drugsline.net
  19. drugswebonline.com
  20. echeap-drugs.com
  21. extracheapdrugs.com
  22. firm-pharmacy.com
  23. freewebdav.com
  24. ftonk.com
  25. genericdrugsareus.com
  26. gldpharmacy.com
  27. govardwool.com
  28. idrugmall.com
  29. janomestaging.com
  30. jofk.com
  31. love-pharmacy.org
  32. many-shop.com
  33. medications.stimulhosting.com
  34. medprivacy.net
  35. my-web-pills.com
  36. ns0.stimulhosting.com
  37. ns1.alfapills.com
  38. ns1.buy-pharmacy.info
  39. ns1.cvs-pharmacy.biz
  40. ns1.love-pharmacy.org
  41. ns1.medm.net
  42. ns1.pharmacyvia.net
  43. ns1.pittlearningsolutions.net
  44. ns1.stimulhosting.com
  45. ns1.worldsbestpharmacy.net
  46. ns2.alfapills.com
  47. ns2.buy-pharmacy.info
  48. ns2.cvs-pharmacy.biz
  49. ns2.love-pharmacy.org
  50. ns2.medm.net
  51. ns2.pharmacyvia.net
  52. ns2.pittlearningsolutions.net
  53. ns1.stimulhosting.com
  54. ns1.worldsbestpharmacy.net
  55. ns2.alfapills.com
  56. ns2.buy-pharmacy.info
  57. ns2.cvs-pharmacy.biz
  58. ns2.love-pharmacy.org
  59. ns2.medm.net
  60. ns2.pharmacyvia.net
  61. ns2.pittlearningsolutions.net
  62. ns2.worldsbestpharmacy.net
  63. onlinepharmacyfda.com
  64. order-cheap-meds.com
  65. orgasm-drugstore.com
  66. ovvl.com
  67. parcialis.com
  68. pharma37.com
  69. pharmacy-54.com
  70. pharmacytop.com
  71. pharmacyvia.net
  72. pharmamexpills.com
  73. pharmamexstore.com
  74. pharmamixx.com
  75. pharmocean.com
  76. pill-s.net
  77. pills-buy-now.com
  78. pillsmarket.net
  79. pillsstore.net
  80. relay.alfapills.com
  81. relay.buy-pharmacy.info
  82. relay.cvs-pharmacy.biz
  83. relay.love-pharmacy.org
  84. relay.medm.net
  85. relay.my-web-pills.com
  86. relay.nypdfoyle.com
  87. relay.pharmacyvia.net
  88. relay.pill-s.net
  89. relay.worldsbestpharmacy.net
  90. retreadthreads.com
  91. rksu.com
  92. rpvo.com
  93. rx-review.com
  94. s-pills.com
  95. shinkatech.com
  96. sleline.com
  97. stimulhosting.com
  98. takeyourdrug.com
  99. thedrugmarket.com
  100. thepharmacy24.com
  101. top-medications.com
  102. ukusdrugs.com
  103. unkp.com
  104. usadrugsite.com
  105. viagr.net
  106. vkak.com
  107. wdxp.com
  108. wkum.com
  109. worldsbestpharmacy.net
  110. wvvd.com
  111. your-tablets.com

FDA Warns of andersenpharmacy.com & dukepharmacy.com

Buying Prescription Scam Alert 1Drugs Online May Be Dangerous Says Drug Enforcement Administration

DEA Logo - Buying Percription Drugs

National Association of Boards of Pharmacy (NABP)

Warning

“The Canadian Pharmacy, Canadian/European Pharmacy”, “Canadian Healthcare” and “US Drugstore” are brands of one of the most disgusting illegal online pharmacy group well organized CRIMINAL OPERATION of all times. “GREED” is the driving force behind this operation. Don’t let them fool you. They will never send you any genuine drugs. If they ever send anything at all, it may consist of literally anything from sugar to wall plaster, and they certainly don’t care that you will endanger your health by taking those dangerous counterfeit drugs.

Behind The Online Pharmacy

Today a shadowy, transnational network of illicit drug manufacturers, traders, doctors, Web site operators, spammers and criminals makes up the online pharmacy world.

Buying Medication Online Can Be Safe

There are many options out there when it comes to buying medication online. We have looked at websites after websites. Some sites feature offshore pharmacies that do not require a prior prescription. Others feature licensed pharmacies that do require a prescription from your doctor.
Before making a purchase that can effect your health, we strongly recommend that you consult your physician & DO NOT self-medicate. Ordering medication online can be a safe, money-saving experience. When done through licensed online pharmacies that require a prescription, you can be assured that the medication you get is exactly what you need to treat your ailments.

 


From: FDA Center for Drug Evaluation and Research
FDAlnternetPharmacyTaskForce-CDER@fda.hhs.gov

Date: November 16, 2009

 

TO: William Wynne
billandsveta@hotmail.com

UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
ROCKVILLE, MD 20903

TO: William Wynne
FROM: Food and Drug Administration Internet Pharmacy Task Force
RE: Internet Marketing of Unapproved and Misbranded Drugs
DATE: November 16, 2009

Warning Letter

The United States Food and Drug Administration (FDA) has reviewed your websites at andersenpharmacy.com and dukepharmacy.com and has determined that you are offering products for sale in violation of the Federal Food, Drug, and Cosmetic Act (the Act). These products include, but are not limited to “Acomplia (Brand),” “Acomplia (Generic) “Rimonabant,” “Herbal Ambien,” “Herbal Xanax,” “Valium (Brand),” “Valium (Generic),” and “Prozac (Generic).” We request that you immediately cease marketing violative products.

These products are drugs under section 201 (g) of the Act, 21 U.S.C. § 321 (g), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or because they are intended to affect the structure or function of the body. Your marketing and distribution of these drugs violate various provisions of the Act, as described below:

Unapproved New Drugs

Your firm offers many unapproved new drugs including, but not limited to “Acomplia (Brand),” “Acomplia (Generic),” “Rimonabant,” “Herbal Ambien,” and “Herbal Xanax.” FDA is taking this action against your firm because of the inherent risk in buying unapproved prescription drugs. Unapproved drugs from unregulated sources do not have the same assurance of safety and effectiveness as drugs subject to FDA oversight and have been found to be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients
altogether. For drugs that are regulated by FDA, FDA protections include rigorous scientific standards for prescription drug approval and label review for accuracy and completeness, manufacturing procedures and testing performed under closely controlled conditions at FDA registered and inspected facilities. In addition, pharmacies and wholesalers who sell or distribute prescription drugs in the U.S. are licensed by the states. Unapproved new drugs delivered to the American public from unregulated sources may not be safe and effective.

Rimonabant (also marketed under the name Acomplia) was specifically rejected for FDA approval because it did not meet the statutory requirements for safety and effectiveness. In June 2007, the FDA Endocrinologic and Metabolic Drugs Advisory Committee unanimously voted not to recommend approval of the drug because of increased risk of neurological and psychiatric side effects including seizures, depression, anxiety, insomnia, aggressiveness, and suicidal thoughts among patients. Accordingly, the “Acomplia (Brand),” “Acomplia (Generic),” and “Rimonabant” dispensed through your websites are “new drugs,” as defined by section 201 (p) of the Act, 21 U.S.C. § 321 (p).

You also offer “Herbal Ambien,” and “Herbal Xanax,” on your websites. Ambien and Xanax are approved drugs well-known for their intended use(s) to treat disease. Therefore, including these drug names causes “Herbal Ambien” and “Herbal Xanax” to be subject to regulation as drugs under Section 201 (g) of the Act because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease. Moreover, these products are new drugs, as defined by section 201 (p) of the Act, 21 U.S.C. § 321 (p).

Under sections 301 (d) and 505(a) of the Act, 21 U.S.C. §§ 331 (d) and 355(a), a new drug may not be introduced or delivered for introduction into interstate commerce unless an FDA-approved application is in effect for it. Your sale of several products, including “Acomplia (Brand),” “Acomplia (Generic),” “Rimonabant,” “Herbal Ambien,” and “Herbal Xanax” without approved applications violates these provisions of the Act.

Misbranded Drugs

Your websites offer numerous products, including but not limited to “Valium (Brand),” “Valium (Generic),” and “Prozac (Generic),” for sale without requiring that the products be dispensed under a prescription from a duly licensed practitioner. Some of the products available on your website are also controlled substances; the sale of these products is particularly concerning because of the potential for abuse and dependency. Therefore, the drugs are misbranded under section 503(b)(1) of the Act, 21 U.S.C. § 353(b)(1), and are marketed in violation of sections 301 (a), 301 (b), and 301 (k) of such Act, 21 U.S.C. §§ 331 (a), 331 (b), and 331 (k).

Further, your websites offer products for sale and state that they are FDA-approved. As noted above, your products are not FDA-approved and are offered for sale in violation of the Act. Therefore, these products are misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because the labeling of the drugs is false and misleading.

In addition, you offer “Herbal Ambien” and “Herbal Xanax” for sale. These drugs are misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because their labeling is false and misleading. The labeling is false and misleading because it erroneously suggest that the products contain Ambien or Xanax, which are the proprietary names for FDA-approved products containing the active pharmaceutical ingredient zolpidem and alprazolam. Regardless of whether your products contain Ambien or Xanax, the products you are offering for sale are not manufactured by the sponsors of the approved applications for Ambien and Xanax, and it is false and misleading to suggest that your products are manufactured by those sponsors.

The introduction or delivery for introduction into interstate commerce of these misbranded products violates section 301 (a) of the Act, 21 U.S.C. § 331 (a).

This letter is not intended to identify all of the ways in which your activities might be in violation of United States law. It is your responsibility to ensure that all products marketed by your firm are in compliance with the Act and its implementing regulations. You should take prompt action to correct the violations noted above. Failure to correct these violations promptly may result in regulatory action, including but not limited to, seizure and/or injunction without further notice.

Please notify this office in writing within 15 working days of receipt of this letter of any steps you have taken or will take to correct the noted violations and to prevent their recurrence. If the corrective action(s) cannot be completed within 15 working days, state the reason for the delay and the time within which the correction(s) will be completed. Your response should be sent to FDA lnternet Pharmacy  TaskForce-CDER@fda.hhs.gov. Please direct any inquiries concerning this letter to FDA’s Internet Pharmacy Task Force at AlnternetPharmacyTaskForceCDER@fda.hhs.gov or (301) 796-3110.

Sincerely,

/S/

Deborah M. Autor, Esq.
Director
Office of Compliance
Center for Drug Evaluation and Research

 


 

Address lookup

lookup failed andersenpharmacy.com
Could not find an IP address for this domain name.

Domain Whois record

Queried whois.internic.net with “dom andersenpharmacy.com”…

   Domain Name: ANDERSENPHARMACY.COM
   Registrar: WILD WEST DOMAINS, INC.
   Whois Server: whois.wildwestdomains.com
   Referral URL: http://www.wildwestdomains.com
   Name Server: NS1.SUSPENDED-FOR.SPAM-AND-ABUSE.COM
   Name Server: NS2.SUSPENDED-FOR.SPAM-AND-ABUSE.COM
   Status: clientDeleteProhibited
   Status: clientRenewProhibited
   Status: clientTransferProhibited
   Status: clientUpdateProhibited
   Updated Date: 17-nov-2009
   Creation Date: 29-oct-2005
   Expiration Date: 29-oct-2010

>>> Last update of whois database: Sun, 22 Nov 2009 08:53:01 UTC <<<

Queried whois.wildwestdomains.com with “andersenpharmacy.com”…

Registrant:
   OMR

   Registered through: JoJoDomains.com
   Domain Name: ANDERSENPHARMACY.COM

   Domain servers in listed order:
      NS1.SUSPENDED-FOR.SPAM-AND-ABUSE.COM
      NS2.SUSPENDED-FOR.SPAM-AND-ABUSE.COM

   For complete domain details go to:

Network Whois record

Don’t have an IP address for which to get a record

DNS records

DNS query for andersenpharmacy.com failed: WouldBlock

No records to display

– end –

WhoIs wellknowndrugs.com – FDA Warns

Buying Prescription Scam Alert 1Drugs Online May Be Dangerous Says Drug Enforcement Administration

DEA Logo - Buying Percription Drugs

National Association of Boards of Pharmacy (NABP)

Warning

“The Canadian Pharmacy, Canadian/European Pharmacy”, “Canadian Healthcare” and “US Drugstore” are brands of one of the most disgusting illegal online pharmacy group well organized CRIMINAL OPERATION of all times. “GREED” is the driving force behind this operation. Don’t let them fool you. They will never send you any genuine drugs. If they ever send anything at all, it may consist of literally anything from sugar to wall plaster, and they certainly don’t care that you will endanger your health by taking those dangerous counterfeit drugs.

Behind The Online Pharmacy

Today a shadowy, transnational network of illicit drug manufacturers, traders, doctors, Web site operators, spammers and criminals makes up the online pharmacy world.

Buying Medication Online Can Be Safe

There are many options out there when it comes to buying medication online. We have looked at websites after websites. Some sites feature offshore pharmacies that do not require a prior prescription. Others feature licensed pharmacies that do require a prescription from your doctor.
Before making a purchase that can effect your health, we strongly recommend that you consult your physician & DO NOT self-medicate. Ordering medication online can be a safe, money-saving experience. When done through licensed online pharmacies that require a prescription, you can be assured that the medication you get is exactly what you need to treat your ailments.



From: FDA Center for Drug Evaluation and Research
FDAlnternetPharmacyTaskForce-CDER@fda.hhs.gov

Date: November 16, 2009

 

Food and Drug Administration
TO: Eugene Lefter
peachpiefordiabetics@gmail.com

UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
ROCKVILLE, MD 20903

TO: Eugene Lefter
FROM: Food and Drug Administration Internet Pharmacy Task Force
RE: Internet Marketing of Unapproved and Misbranded Drugs
DATE: November 16,2009

Warning Letter

The United States Food and Drug Administration (FDA) has reviewed your website at wellknowndrugs.com and has determined that you are offering products for sale in violation of the Federal Food, Drug, and Cosmetic Act (the Act). These products include, but are not limited to “Acomplia (Generic),” “Valium (Brand),” and “Xanax (Generic).” We request that you immediately cease marketing violative products.

These products are drugs under section 201 (g) of the Act, 21 U.S.C. § 321 (g), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or because they are intended to affect the structure or function of the body. Your marketing and distribution of these drugs violate various provisions of the Act, as described below:

Unapproved New Drugs

Your firm offers unapproved new drugs including, but not limited to “Acomplia (Generic).” FDA is taking this action against your firm because of the inherent risk in buying unapproved prescription drugs. Unapproved drugs from unregulated sources do not have the same assurance of safety and effectiveness as drugs subject to FDA oversight and have been found to be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether. For drugs that are regulated by FDA, FDA protections include rigorous scientific standards for prescription drug approval and label review for accuracy and completeness, manufacturing procedures and testing performed under closely controlled conditions at FDA registered and inspected facilities. In addition, pharmacies and wholesalers who sell or distribute prescription drugs in the U.S. are licensed by the states. Unapproved new drugs delivered to the American public from unregulated sources may not be safe and effective.

Rimonabant (also marketed under the name Acomplia) was specifically rejected for FDA approval because it did not meet the statutory requirements for safety and effectiveness. In June 2007, the FDA Endocrinologic and Metabolic Drugs Advisory Committee unanimously voted not to recommend approval of the drug because of increased risk of neurological and psychiatric side effects including seizures, depression, anxiety, insomnia, aggressiveness, and suicidal thoughts
among patients. Accordingly, the “Acomplia (Generic)” dispensed through your website is a “new drug,” as defined by section 201 (p) of the Act, 21 U.S.C. § 321 (p).

Under sections 301 (d) and 505(a) of the Act, 21 U.S.C. §§ 331 (d) and 355(a), a new drug may not be introduced or delivered for introduction into interstate commerce unless an FDA-approved application is in effect for it. Your sale of several products, including “Acomplia (Generic),” without approved applications violates these provisions of the Act.

Misbranded Drugs

Your website offers products, including but not limited to “Valium (Brand)” and “Xanax (Generic)” for sale without requiring that the products be dispensed under a prescription from a duly licensed practitioner. Some of the products available on your website are also controlled substances; the sale of these products is particularly concerning because of the potential for abuse and dependency. Therefore, the drugs are misbranded under section 503(b)(1) of the Act, 21 U.S.C. § 353(b)(1), and are marketed in violation of sections 301 (a), 301 (b), and 301 (k) of such Act, 21 U.S.C. §§ 331 (a), 331(b), and 331(k).

Further, your website offers products for sale and states that they are FDA-approved. As noted above, your products are not FDA-approved and are offered for sale in violation of the Act.
Therefore, these products are misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because the labeling of the drugs is false and misleading.

The introduction or delivery for introduction into interstate commerce of these misbranded products violates section 301 (a) of the Act, 21 U.S.C. § 331 (a).

This letter is not intended to identify all of the ways in which your activities might be in violation of United States law. It is your responsibility to ensure that all products marketed by your firm are in compliance with the Act and its implementing regulations. You should take prompt action to correct the violations noted above. Failure to correct these violations promptly may result in regulatory action, including but not limited to, seizure and/or injunction without further notice.

Please notify this office in writing within 15 working days of receipt of this letter of any steps you have taken or will take to correct the noted violations and to prevent their recurrence. If the corrective action(s) cannot be completed within 15 working days, state the reason for the delay and the time within which the correction(s) will be completed. Your response should be sent to FDAlnternetPharmacyTaskForce-CDER@fda.hhs.gov. Please direct any inquiries concerning this letter to FDA’s Internet Pharmacy Task Force at FDAlnternetPharmacyTaskForceCDER@fda.hhs.gov or (301) 796-3110.

Sincerely,

/S/
Deborah M. Autor, Esq.
Director
Office of Compliance
Center for Drug Evaluation and Research

 


 

Address lookup

lookup failed wellknowndrugs.com
Could not find an IP address for this domain name.

Domain Whois record

Queried whois.internic.net with “dom wellknowndrugs.com”…
Domain Name: WELLKNOWNDRUGS.COM
Registrar: MONIKER ONLINE SERVICES, INC.
Whois Server: whois.moniker.com
Referral URL: http://www.moniker.com/whois.html
Name Server: No nameserver
Status: clientDeleteProhibited
Status: clientHold
Status: clientTransferProhibited
Updated Date: 17-nov-2009
Creation Date: 31-dec-2008
Expiration Date: 31-dec-2009
Last update of whois database: Sun, 22 Nov 2009 08:41:15 UTC
Queried whois.moniker.com with “wellknowndrugs.com”…
Domain Name: WELLKNOWNDRUGS.COM
Registrar: MONIKER

Registrant [1913944]:
Eugen Lefter peachpiefordiabetics@gmail.com
Student 17/1
Ch
Ch
3001
MD

Administrative Contact [1913944]:
Eugen Lefter peachpiefordiabetics@gmail.com
Student 17/1
Ch
Ch
3001
MD
Phone: +373.79656020

Billing Contact [1913944]:
Eugen Lefter peachpiefordiabetics@gmail.com
Student 17/1
Ch
Ch
3001
MD
Phone: +373.79656020

Technical Contact [1913944]:
Eugen Lefter peachpiefordiabetics@gmail.com
Student 17/1
Ch
Ch
3001
MD
Phone: +373.79656020

Domain servers in listed order:

NS1.ALLSITESDNS.COM
NS2.ALLSITESDNS.COM

Record created on: 2008-12-31 10:29:27.0
Database last updated on: 2009-10-07 16:17:56.33
Domain Expires on: 2009-12-31 10:29:28.0

Network Whois record

Don’t have an IP address for which to get a record

DNS records

DNS query for wellknowndrugs.com returned an error from the server: NameError

No records to display

FDA Warns of Xanos Holdings Inc – usrxmeds.net

Buying Prescription Scam Alert 1Drugs Online May Be Dangerous Says Drug Enforcement Administration


DEA Logo - Buying Percription Drugs

National Association of Boards of Pharmacy (NABP)

Warning

“The Canadian Pharmacy, Canadian/European Pharmacy”, “Canadian Healthcare” and “US Drugstore” are brands of one of the most disgusting illegal online pharmacy group well organized CRIMINAL OPERATION of all times. “GREED” is the driving force behind this operation. Don’t let them fool you. They will never send you any genuine drugs. If they ever send anything at all, it may consist of literally anything from sugar to wall plaster, and they certainly don’t care that you will endanger your health by taking those dangerous counterfeit drugs.

Behind The Online Pharmacy

Today a shadowy, transnational network of illicit drug manufacturers, traders, doctors, Web site operators, spammers and criminals makes up the online pharmacy world.

Buying Medication Online Can Be Safe

There are many options out there when it comes to buying medication online. We have looked at websites after websites. Some sites feature offshore pharmacies that do not require a prior prescription. Others feature licensed pharmacies that do require a prescription from your doctor.
Before making a purchase that can effect your health, we strongly recommend that you consult your physician & DO NOT self-medicate. Ordering medication online can be a safe, money-saving experience. When done through licensed online pharmacies that require a prescription, you can be assured that the medication you get is exactly what you need to treat your ailments.


From: FDA Center for Drug Evaluation and Research
FDAlnternetPharmacyTaskForce-CDER@fda.hhs.gov

Date: November 16, 2009
TO: Xanos Holdings Inc.
34 Europa Rd, PE24 4
Gibraltar
UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICES

FOOD AND DRUG ADMINISTRATION
ROCKVILLE, MD 20903

 

TO: Xanos Holdings Inc.
FROM: Food and Drug Administration Internet Pharmacy Task Force
RE: Internet Marketing of Unapproved and Misbranded Drugs
DATE: November 16, 2009

Warning Letter


The United States Food and Drug Administration (FDA) has reviewed your websites at direct-pharm.com, us-value-pharm.com, global-drugstore.com, refill-club.com, global-generics-source.com, european-drugstore.com, first-canadian-pharm.com, mexican-pharm.com, pillsshipping.com, rxgenericsstore.com, americanmedsdirect.com, and usrxmeds.net and has determined that you are offering products for sale in violation of the Federal Food, Drug, and Cosmetic Act (the Act). These products include, but are not limited to,  “Acomplia (Generic),” “Acomplia (Brand),” “Rimonabant,” “Viagra (Brand),” “Cialis (Brand),” “Prozac (Generic),” and “Levitra (Brand).” We request that you immediately cease marketing violative products.
These products are drugs under section 201 (g) of the Act, 21 U.S.C. § 321 (g), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or because they are intended to affect the structure or function of the body. Your marketing and distribution of these drugs violate various provisions of the Act, as described below:
Unapproved New Drugs
Your firm offers many unapproved new drugs including, but not limited to “Acomplia (Generic),” “Acomplia (Brand),” and “Rimonabant.” FDA is taking this action against your firm because of the inherent risk in buying unapproved prescription drugs. Unapproved drugs from unregulated sources do not have the same assurance of safety and effectiveness as drugs subject to FDA oversight and have been found to be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether. For drugs that are regulated by FDA, FDA protections include rigorous scientific standards for prescription drug approval and label review for accuracy and completeness, manufacturing procedures and testing performed under closely controlled conditions at FDA-registered and inspected facilities. In addition, pharmacies and wholesalers who sell or distribute prescription drugs in the U.S. are licensed by the states. Unapproved new drugs delivered to the American public from unregulated sources may not be safe and effective.
Rimonabant (also marketed under the name Acomplia) was specifically rejected for FDA approval because it did not meet the statutory requirements for safety and effectiveness. In June 2007, the FDA Endocrinologic and Metabolic Drugs Advisory Committee unanimously voted not to recommend approval of the drug because of increased risk of neurological and psychiatric side effects including seizures, depression, anxiety, insomnia, aggressiveness, and suicidal thoughts among patients. Accordingly, the “Acomplia (Generic),” “Acomplia (Brand),” and “Rimonabant” dispensed through your websites are “new drugs,” as defined by section 201 (p) of the Act, 21 U.S.C. § 321(p).
Under sections 301(d) and 505(a) of the Act, 21 U.S.C. §§ 331 (d) and 355(a), a new drug may not be introduced or delivered for introduction into interstate commerce unless an FDA-approved application is in effect for it. Your sale of several products, including “Acomplia (Generic),” “Acomplia (Brand),” and “Rimonabant” without approved applications violates these provisions of the Act.
Misbranded Drugs
Many of your websites sell products, including but not limited to “Viagra (Brand),” “Cialis (Brand),” “Prozac (Generic),” and “Levitra (Brand),” without requiring that the products be dispensed under a prescription from a duly licensed practitioner. Therefore, the drugs are misbranded under section 503(b)(1) of the Act, 21 U.S.C. § 353(b)(1), and are marketed in violation of sections 301 (a), 301 (b), and 301 (k) of such Act, 21 U.S.C. §§ 331 (a), 331 (b), and 331 (k).
Further, your websites offer products for sale and state that they are FDA-approved. As noted above, your products are not FDA-approved and are offered for sale in violation of the Act. Therefore, these products are misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because the labeling of the drugs is false and misleading.
The introduction or delivery for introduction into interstate commerce of these misbranded products violates section 301 (a) of the Act, 21 U.S.C. § 331 (a).
This letter is not intended to identify all of the ways in which your activities might be in violation of United States law. It is your responsibility to ensure that all products marketed by your firm are in compliance with the Act and its implementing regulations. You should take prompt action to correct the violations noted above. Failure to correct these violations promptly may result in regulatory action, including but not limited to, seizure and/or injunction without further notice.
Please notify this office in writing within 15 working days of receipt of this letter of any steps you have taken or will take to correct the noted violations and to prevent their recurrence. If the corrective action(s) cannot be completed within 15 working days, state the reason for the delay and the time within which the correction(s) will be completed. Your response should be sent to FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov. Please direct any inquiries concerning this letter to FDA’s Internet Pharmacy Task Force at FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov or (301) 796-3110.
Sincerely,
/S/

Deborah M. Author, Esq.

Director
Office of Compliance
Center for Drug Evaluation and Research
Cc:
Chris Walsh c/o Dynadot Privacy
P.O. Box 701
San Mateo, CA 94401
direct-pharm.com
global-generics-source.com
Katrina Boykin c/o Dynadot Privacy
PO Box 701
San Mateo, CA 94401
us-value-pharm.com
Marilyn Strongin c/o Dynadot Privacy
PO Box 701
San Mateo, CA 94401
global-drugstore.com
PrivacyProtect.org
contact@privacyprotect.org
refill-club.com
European-drugstore.com
first-canadian-pharm.com
Mexican-pharm.com
HW
Oleg Abdulevskiy
Russ
Sarataf, RU 410030
RU
starttech12@gmx.de
pillsshipping.com
Nexton Limited
Ryabov Sergey
Scherbakova st., 6-38
Saint-Petersburg, RU 197375
director@climbing-games.com
rxgenericsstore.com

Protected Domain Services – Customer ID: NCR-861681
125 Rampart Way, Suite 300
Denver, CO 80230
americanmedsdirect.com@protecteddomainservices.com
americanmedsdirect.com
WhoisGuard
8939 S. Sepulveda Blvd. #110 – 732
Westchester, CA 90045
usrxmeds.net


More Sites Associated With This Group
1. Callcenter-sales.com
2. Dietpillsworldwide.com
3. E-z-diet-pills.com
4. Epharmace.com
5. Herbals-rx.com
6. Licensed-meds.com
7. Medsworldwidenetwork.com
8. My-pharm.com
9. Pill-planet.com
10. Pillswithcare.com
11. Planetgenerics.net
12. Presidentrx.com
13. Rx-brokers.com
14. Rx-checkout.net
15. Rx-life.com
16. Rx-today.net
17. The-pharmacy.us
18. Total-meds.com
19. Value-pharm.com
20. Wholesale-generics.com
21. Worldshippingmeds.com
22. Your-pharmacy.us
23. Iwebpharmacy.com

 

Follow

Get every new post delivered to your Inbox.